Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

Clinical trial NCT01500226 · COMPLETED

Trial details

NCT number: NCT01500226
Sponsor: Tesaro, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chemotherapy-induced Nausea and Vomiting

Start date: 2012-02-01
Primary completion: 2014-02-01
Enrollment: 1369

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.